Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer

NICE technology appraisals [TA258] Published date:

NICE recommends erlotinib as a possible first-line treatment (that is, if you have not had drug treatment before) for some people with locally advanced or metastatic non-small-cell lung cancer (see below).

Who can have erlotinib?
You should be able to have erlotinib if you have a type of locally advanced or metastatic non-small-cell lung cancer that has tested positive for mutations (changes) to EGFR-TK (which stands for epidermal growth factor receptor tyrosine kinase) in the cancer cells.

Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommended erlotinib because it works as well other treatments available on the NHS, and costs about the same.

Get involved